Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back to main page
NEW:
Evidence
Click below to explore the latest additions to VERI
Click below to explore the latest additions to VERI
Biomarkers (12)
Genes (4)
Drugs (1)
Tests (1)
Evidence (12)
Biomarker (9)
HER-2 amplification
HER-2 positive
HER-2 underexpression
HR positive
MSI-H/dMMR
No biomarker
PD-L1 expression
PIK3CA mutation + AKT mutation + PTEN mutation
SMARCA4 deletion
Cancer type (8)
Breast Cancer
Cervical Cancer
Cholangiocarcinoma
Diffuse Large B Cell Lymphoma
Endometrial Cancer
HER2 Negative Breast Cancer
Non Small Cell Lung Cancer
Solid Tumor
Therapy (10)
ARQ 751
CT-0508
cemiplimab
dostarlimab
fam-trastuzumab deruxtecan-nxki
lisocabtagene maraleucel
nivolumab
pembrolizumab
pembrolizumab + lenvatinib + pyrotinib
ribociclib
No biomarker
No biomarker
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: B - Late Trials
Bristol-Myers Squibb Press Release - Today
lisocabtagene maraleucel
Sensitive: B - Late Trials
Bristol-Myers Squibb Press Release - Today
PD-L1 expression
PD-L1 expression
Cervical Cancer
Cervical Cancer
pembrolizumab
Sensitive: A2 - Guideline
Precision Oncology News - 2 days
pembrolizumab
Sensitive: A2 - Guideline
Precision Oncology News - 2 days
MSI-H/dMMR
MSI-H/dMMR
Solid Tumor
Solid Tumor
pembrolizumab
Sensitive: A1 - Approval
FDA - 2 days
pembrolizumab
Sensitive: A1 - Approval
FDA - 2 days
PD-L1 expression
PD-L1 expression
Non Small Cell Lung Cancer
NSCLC
cemiplimab
Sensitive: A1 - Approval
Regeneron Pharmaceuticals Press Release - 2 days
cemiplimab
Sensitive: A1 - Approval
Regeneron Pharmaceuticals Press Release - 2 days
HER-2 positive
HER-2 positive
Solid Tumor
Solid Tumor
CT-0508
Sensitive: D – Preclinical
J Transl Med - 3 days
CT-0508
Sensitive: D – Preclinical
J Transl Med - 3 days
HER-2 amplification
HER-2 amplification
Cholangiocarcinoma
Cholangiocarcinoma
pembrolizumab + lenvatinib + pyrotinib
Sensitive: C4 – Case Studies
World J Surg Oncol - 4 days
pembrolizumab + lenvatinib + pyrotinib
Sensitive: C4 – Case Studies
World J Surg Oncol - 4 days
SMARCA4 deletion
SMARCA4 deletion
Non Small Cell Lung Cancer
NSCLC
nivolumab
Sensitive: C4 – Case Studies
Front Immunol - 4 days
nivolumab
Sensitive: C4 – Case Studies
Front Immunol - 4 days
PIK3CA mutation + AKT mutation + PTEN mutation
PIK3CA mutation + AKT mutation + PTEN mutation
Solid Tumor
Solid Tumor
ARQ 751
Sensitive: C3 – Early Trials
Cancer - 4 days
ARQ 751
Sensitive: C3 – Early Trials
Cancer - 4 days
MSI-H/dMMR
MSI-H/dMMR
Endometrial Cancer
Endometrial Cancer
dostarlimab
Sensitive: B - Late Trials
N Engl J Med - 4 days
dostarlimab
Sensitive: B - Late Trials
N Engl J Med - 4 days
HR positive
HR positive
HER2 Negative Breast Cancer
HER2 Negative Breast Cancer
ribociclib
Sensitive: B - Late Trials
Novartis Press Release - 4 days
ribociclib
Sensitive: B - Late Trials
Novartis Press Release - 4 days
No biomarker
No biomarker
Non Small Cell Lung Cancer
NSCLC
nivolumab
Sensitive: A1 - Approval
Ono Pharmaceuticals Press Release - 4 days
nivolumab
Sensitive: A1 - Approval
Ono Pharmaceuticals Press Release - 4 days
HER-2 underexpression
HER-2 underexpression
Breast Cancer
Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
Daiichi Sankyo Press Release - 4 days
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
Daiichi Sankyo Press Release - 4 days
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login